ALZN (Alzamend Neuro) Short-Term Debt: $0.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALZN Alzamend Neuro Inc ALZN
21 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is Alzamend Neuro Short-Term Debt?

Alzamend Neuro ALZN +0.75% 21 Short-Term Debt is $0.00 Mil as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Alzamend Neuro's Short-Term Debt for the quarter that ended in Apr. 2026 was $0.00 Mil.

Alzamend Neuro's annual Short-Term Debt declined from Apr. 2024 ($0.30 Mil) to Apr. 2025 ($0.00 Mil) but then stayed the same from Apr. 2025 ($0.00 Mil) to Apr. 2026 ($0.00 Mil).

Alzamend Neuro Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Alzamend Neuro Short-Term Debt Related Terms

Alzamend Neuro Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Alzamend Neuro's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro Short-Term Debt Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.30 0.00 0.00

Alzamend Neuro Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALZN
21GF Score
Alzamend Neuro Inc ALZN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Alzamend Neuro (ALZN) has a Short-Term Debt of $0.00 Mil as of Apr. 2026.
Is Alzamend Neuro's Short-Term Debt too high?
Alzamend Neuro's current Short-Term Debt is $0.00 Mil. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's Short-Term Debt compare to SILO and BGMS?
Alzamend Neuro's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Alzamend Neuro's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current Short-Term Debt is $0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzamend Neuro Business Description

Address 3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score

Get the complete analysis for ALZN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price